Skip to content

Neuropace, Inc. NPCE Preferred Stock, Par or Stated Value Per Share

Preferred Stock, Par or Stated Value Per Share at other companies

ClearPoint Neuro logo
ClearPoint NeuroCLPT
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s preferred stock, par or stated value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s preferred stock, par or stated value per share?
Neuropace, Inc. (NPCE) reported preferred stock, par or stated value per share of $0 in Q1 2026.
How has Neuropace, Inc.'s preferred stock, par or stated value per share changed year-over-year?
Neuropace, Inc.'s preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Neuropace, Inc.'s preferred stock, par or stated value per share?
Over 5 years (2020 to 2025), Neuropace, Inc.'s preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.